Preferred Label : Vedolizumab;
NCIt synonyms : Immunoglobulin G1, Anti-(Human Integrin LPAM-1 (Lymphocyte Peyer's Patch Adhesion
Molecule 1)) (Human-Mus musculus Heavy Chain), Disulfide with Human-Mus musculus kappa-chain,
Dimer;
NCIt definition : A recombinant humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against
the human lymphocyte Peyer's patch adhesion molecule 1 (LPAM-1; alpha4beta7; a4b7),
with immunomodulating, anti-inflammatory, and potential antineoplastic activities.
Upon administration, vedolizumab selectively binds to integrin a4b7 and prevents the
binding of a4b7, expressed on the surface of a subset of T-lymphocytes, to its natural
ligand, mucosal addressin cell adhesion molecule-1 (MAdCAM-1), which is mainly expressed
on the surface of gut endothelial cells. This prevents a4b7-mediated signaling, adhesion
of lymphocytes to the endothelium and the migration of T-lymphocytes across the endothelium
into inflamed gastrointestinal (GI) tissue. By preventing this infiltration to the
affected area, inflammation is reduced. The human lymphocyte a4b7 integrin, plays
a key role in gastrointestinal (GI) inflammation; it is overexpressed in certain types
of cancer cells. The alpha4beta7/MAdCAM-1 signaling pathway plays a critical role
in the homing of T-lymphocytes to intestinal tissue.;
UNII : 9RV78Q2002;
CAS number : 943609-66-3;
Drug name : Entyvio;
Molecule name : MLN0002; MLN02; LDP-02; LDP 02;
Origin ID : C95798;
UMLS CUI : C2742797;
CISMeF manual mappings
Currated CISMeF NLP mapping
See also inter- (CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
chemical_or_drug_has_mechanism_of_action
concept_is_in_subset
has_target
https://assurance-maladie.ameli.fr/etudes-et-donnees/2024-vedolizumab-ustekinumab-anti-tnf-grossesse-mici
2024
France
scientific and technical information
safety
TNF Gene
Ustekinumab
inflammatory bowel disease, nos
tumor necrosis factor
Institutional Review Board Independent Ethics Committee Notification of Safety Information
Documentation
Physically Feel in Bad Condition
tumor necrosis factors
Safety Report
Clinical Trial Notification of Safety or Other Trial Information Documentation
chronic disease, nos
Vedolizumab
research report
vedolizumab
disease
Tumor Necrosis Factor
anti-TNF
Ustekinumab
Chronic Disease
Pregnant People
inflammatory bowel diseases
vedolizumab
pregnancy, nos
albumin/globulin ratio
chronic disease
Gravida
---